Nalidixic acid
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Nalidixic acid
| |
| Systematic (IUPAC) name | |
| 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H12N2O3 |
| Mol. mass | 232.235 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 90% |
| Metabolism | Partially Hepatic |
| Half life | 6-7 hours, significantly longer in renal impairment |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B U.S. |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Nalidixic acid | |
|
Articles | |
|---|---|
|
Most recent articles on Nalidixic acid Most cited articles on Nalidixic acid | |
|
Media | |
|
Powerpoint slides on Nalidixic acid | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Nalidixic acid at Clinical Trials.gov Trial results on Nalidixic acid Clinical Trials on Nalidixic acid at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Nalidixic acid NICE Guidance on Nalidixic acid
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Nalidixic acid Discussion groups on Nalidixic acid Patient Handouts on Nalidixic acid Directions to Hospitals Treating Nalidixic acid Risk calculators and risk factors for Nalidixic acid
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Nalidixic acid | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Nalidixic acid is the basis for quinolone antibiotics.
Nalidixic acid is effective against both gram-positive and gram-negative bacteria. In lower concentrations, it acts bacteriostatically (that is, it inhibits growth and reproduction). In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.
It is especially used in treating urinary tract infections, caused for example by Escherichia coli, Proteus, Shigella, Enterobacter and Klebsiella.
External links
See also
Antibacterials for systemic use: topoisomerase inhibitors - quinolones (J01M) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fluoroquinolones |
| ||||||||
| Other quinolones |
| ||||||||
| †Undergoing clinical trials. ‡ Withdrawn from market. § Veterinary use medications. | |||||||||
de:Nalidixinsäureit:Acido nalidixicoth:กรดนาลิดิซิก
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
